Literature DB >> 21652707

Comparative analysis of different peptidyl-prolyl isomerases reveals FK506-binding protein 12 as the most potent enhancer of alpha-synuclein aggregation.

Angélique Deleersnijder1, Anne-Sophie Van Rompuy, Linda Desender, Hans Pottel, Luc Buée, Zeger Debyser, Veerle Baekelandt, Melanie Gerard.   

Abstract

FK506-binding proteins (FKBPs) are members of the immunophilins, enzymes that assist protein folding with their peptidyl-prolyl isomerase (PPIase) activity. Some non-immunosuppressive inhibitors of these enzymes have neuroregenerative and neuroprotective properties with an unknown mechanism of action. We have previously shown that FKBPs accelerate the aggregation of α-synuclein (α-SYN) in vitro and in a neuronal cell culture model for synucleinopathy. In this study we investigated whether acceleration of α-SYN aggregation is specific for the FKBP or even the PPIase family. Therefore, we studied the effect of several physiologically relevant PPIases, namely FKBP12, FKBP38, FKBP52, FKBP65, Pin1, and cyclophilin A, on α-SYN aggregation in vitro and in neuronal cell culture. Among all PPIases tested in vitro, FKBP12 accelerated α-SYN aggregation the most. Furthermore, only FKBP12 accelerated α-SYN fibril formation at subnanomolar concentrations, pointing toward an enzymatic effect. Although stable overexpression of various FKBPs enhanced the aggregation of α-SYN and cell death in cell culture, they were less potent than FKBP12. When FKBP38, FKBP52, and FKBP65 were overexpressed in a stable FKBP12 knockdown cell line, they could not fully restore the number of α-SYN inclusion-positive cells. Both in vitro and cell culture data provide strong evidence that FKBP12 is the most important PPIase modulating α-SYN aggregation and validate the protein as an interesting drug target for Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21652707      PMCID: PMC3143632          DOI: 10.1074/jbc.M110.182303

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  76 in total

1.  Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice.

Authors:  Christian Freichel; Manuela Neumann; Theresa Ballard; Veronika Müller; Marie Woolley; Laurence Ozmen; Edilio Borroni; Hans A Kretzschmar; Christian Haass; Will Spooren; Philipp J Kahle
Journal:  Neurobiol Aging       Date:  2006-07-26       Impact factor: 4.673

2.  Screening of immunophilin ligands by quantitative analysis of neurofilament expression and neurite outgrowth in cultured neurons and cells.

Authors:  Danni Liu; H Beal McIlvain; Myles Fennell; John Dunlop; Andrew Wood; Margaret M Zaleska; Edmund I Graziani; Kevin Pong
Journal:  J Neurosci Methods       Date:  2007-04-05       Impact factor: 2.390

3.  Acutely increased cyclophilin a expression after brain injury: a role in blood-brain barrier function and tissue preservation.

Authors:  John B Redell; Jing Zhao; Pramod K Dash
Journal:  J Neurosci Res       Date:  2007-07       Impact factor: 4.164

4.  A Drosophila model of Parkinson's disease.

Authors:  M B Feany; W W Bender
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

5.  In vitro formation of amyloid from alpha-synuclein is dominated by reactions at hydrophobic interfaces.

Authors:  Jeremy Pronchik; Xianglan He; Jason T Giurleo; David S Talaga
Journal:  J Am Chem Soc       Date:  2010-07-21       Impact factor: 15.419

6.  Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.

Authors:  Andisheh Eslamboli; Marina Romero-Ramos; Corinna Burger; Tomas Bjorklund; Nicholas Muzyczka; Ronald J Mandel; Harry Baker; Rosalind M Ridley; Deniz Kirik
Journal:  Brain       Date:  2007-02-15       Impact factor: 13.501

7.  A role for FKBP52 in Tau protein function.

Authors:  Béatrice Chambraud; Elodie Sardin; Julien Giustiniani; Omar Dounane; Michael Schumacher; Michel Goedert; Etienne-Emile Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-25       Impact factor: 11.205

8.  Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.

Authors:  Melanie Gerard; Angélique Deleersnijder; Veronique Daniëls; Sarah Schreurs; Sebastian Munck; Veerle Reumers; Hans Pottel; Yves Engelborghs; Chris Van den Haute; Jean-Marc Taymans; Zeger Debyser; Veerle Baekelandt
Journal:  J Neurosci       Date:  2010-02-17       Impact factor: 6.167

9.  FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T.

Authors:  Melanie Gerard; Zeger Debyser; Linda Desender; Johan Baert; Inger Brandt; Veerle Baekelandt; Yves Engelborghs
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

10.  Peptidyl-prolyl isomerase FKBP52 controls chemotropic guidance of neuronal growth cones via regulation of TRPC1 channel opening.

Authors:  Sangwoo Shim; Joseph P Yuan; Ju Young Kim; Weizhong Zeng; Guo Huang; Aleksandr Milshteyn; Dorothee Kern; Shmuel Muallem; Guo-li Ming; Paul F Worley
Journal:  Neuron       Date:  2009-11-25       Impact factor: 17.173

View more
  11 in total

Review 1.  The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease.

Authors:  Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2015-01-07       Impact factor: 5.590

2.  A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.

Authors:  T T Myöhänen; M J Hannula; R Van Elzen; M Gerard; P Van Der Veken; J A García-Horsman; V Baekelandt; P T Männistö; A M Lambeir
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  FKBP12 regulates the localization and processing of amyloid precursor protein in human cell lines.

Authors:  Fan-Lun Liu; Ting-Yi Liu; Fan-Lu Kung
Journal:  J Biosci       Date:  2014-03       Impact factor: 1.826

4.  S-nitrosylation of UCHL1 induces its structural instability and promotes α-synuclein aggregation.

Authors:  Roshan Kumar; Deepak K Jangir; Garima Verma; Shashi Shekhar; Pranita Hanpude; Sanjay Kumar; Raniki Kumari; Nirpendra Singh; Neel Sarovar Bhavesh; Nihar Ranjan Jana; Tushar Kanti Maiti
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379

Review 5.  Humanized Mice for Infectious and Neurodegenerative disorders.

Authors:  Prasanta K Dash; Santhi Gorantla; Larisa Poluektova; Mahmudul Hasan; Emiko Waight; Chen Zhang; Milica Markovic; Benson Edagwa; Jatin Machhi; Katherine E Olson; Xinglong Wang; R Lee Mosley; Bhavesh Kevadiya; Howard E Gendelman
Journal:  Retrovirology       Date:  2021-06-05       Impact factor: 3.768

6.  In vitro phosphorylation does not influence the aggregation kinetics of WT α-synuclein in contrast to its phosphorylation mutants.

Authors:  Sarah Schreurs; Melanie Gerard; Rita Derua; Etienne Waelkens; Jean-Marc Taymans; Veerle Baekelandt; Yves Engelborghs
Journal:  Int J Mol Sci       Date:  2014-01-15       Impact factor: 5.923

7.  In vitro screen of prion disease susceptibility genes using the scrapie cell assay.

Authors:  Craig A Brown; Christian Schmidt; Mark Poulter; Holger Hummerich; Peter-C Klöhn; Parmjit Jat; Simon Mead; John Collinge; Sarah E Lloyd
Journal:  Hum Mol Genet       Date:  2014-05-15       Impact factor: 6.150

8.  Identification of a Specific Gene Module for Predicting Prognosis in Glioblastoma Patients.

Authors:  Xiangjun Tang; Pengfei Xu; Bin Wang; Jie Luo; Rui Fu; Kuanming Huang; Longjun Dai; Junti Lu; Gang Cao; Hao Peng; Li Zhang; Zhaohui Zhang; Qianxue Chen
Journal:  Front Oncol       Date:  2019-08-27       Impact factor: 6.244

9.  Blocking the FKBP12 induced dendrimeric burst in aberrant aggregation of α-synuclein by using the ElteN378 synthetic inhibitor.

Authors:  Gabriella Caminati; Maria Raffaella Martina; Stefano Menichetti; Piero Procacci
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

10.  The Molecular Basis of the Interaction of Cyclophilin A with α-Synuclein.

Authors:  Filippo Favretto; Jeremy D Baker; Timo Strohäker; Loren B Andreas; Laura J Blair; Stefan Becker; Markus Zweckstetter
Journal:  Angew Chem Int Ed Engl       Date:  2020-01-29       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.